

23 September 2026

Private Cancer Physicians of Australia
pcpa@amaq.com.au

Extended PBS access to ZOLADEX® (goserelin 3.6 mg implant) in Australia

Dear Private Cancer Physicians of Australia,

AstraZeneca has announced that Zoladex (goserelin 3.6 mg implant) will remain on the Pharmaceutical Benefits Scheme (PBS) until 1 May 2027, after which it will move to a “supply only” arrangement. Prescriptions written before that date may continue to be dispensed for up to 12 months, enabling eligible patients to access PBS-subsidised treatment through to 1 May 2028.

AstraZeneca understands the importance of maintaining PBS access to this therapy and applied for a price increase for the Zoladex monthly (3.6mg) implant to remain on the PBS. The Pharmaceutical Benefits Advisory Committee (PBAC) was unable to grant a price adjustment that would have allowed the continued PBS reimbursement of this medicine.

AstraZeneca will consider making a further application to the PBAC to secure long-term reimbursed access for the Zoladex monthly (3.6mg) implant.

With alternatives now available to Australian patients through the PBS, the previously announced Zoladex continuity program will not proceed.

The separate Zoladex three-monthly (10.8mg) implant is now registered with the Therapeutic Goods Administration for the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women. AstraZeneca awaits the outcome of the PBAC’s evaluation of our submission for a PBS listing of this indication.

Questions can be referred to AstraZeneca’s Medical Information team on telephone 1800 805 342 or via <https://contactazmedical.astrazeneca.com>

We recognise the uncertainty patients and healthcare professionals have experienced and deeply appreciate the contribution of these groups in helping shape these arrangements.

We would welcome the opportunity to hear your perspectives and answer any questions.

Kind regards,



Dr Christina Frenzel

Senior Medical Director, Oncology and Cell Therapy

AstraZeneca Australia and New Zealand

ZOLADEX® (3.6mg) Therapeutic Indications:

- Palliative treatment of metastatic or locally advanced prostate cancer, where suitable, for hormonal manipulation.
- Adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.
- Treatment of advanced breast cancer ((T3b, T4 or any T with N2, 3 or M+)) in premenopausal women suitable for hormonal manipulation.
- Adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation.
- In the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions.
- In the management of fibroids, to shrink lesions and reduce symptoms, including pain. Zoladex® also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. It is used as an adjunct to surgery to facilitate the operative technique and reduce operative blood loss.
- Used as an endometrial thinning agent prior to endometrial ablation.
- In assisted reproduction, for pituitary down regulation in preparation for controlled ovarian superstimulation.

For Zoladex monthly (3.6mg) implant: Please click [here](#) to view full product information before prescribing. PBS Information: Refer to the current [PBS Schedule](#).

ZOLADEX® (10.8mg) Therapeutic Indications:

- Management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and perimenopausal women.

For Zoladex three-monthly (10.8mg) implant: Please click [here](#) to view full product information before prescribing. PBS Information: Refer to the [current PBS Schedule](#).

Further information available on request from AstraZeneca. ZOLADEX is a registered trademark of AstraZeneca. Registered user AstraZeneca Pty Ltd. ABN 54 009 682 311. 66 Talavera Rd, Macquarie Park NSW 2113. www.astrazeneca.com.au For Medical Information enquiries or to report an adverse or product complaint: Telephone 1800 805 342 or via <https://contactazmedical.astrazeneca.com> | AU-27151 September 2026